Licensed pertussis vaccines in the United States: History and current state

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 9, 2014, Pages 2684-2690

  Klein, Nicola P ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Acellular; History; Pertussis; Protection; Vaccines; Waning

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE; PLACEBO; ACELLULAR VACCINE;

BRAIN DISEASE; CLINICAL TRIAL (TOPIC); DIPHTHERIA; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; EPIDEMIC; FEBRILE CONVULSION; HISTORY; HUMAN; HYPOTONIC HYPORESPONSIVE EPISODE; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LICENCE; LIMB SWELLING; LONG TERM CARE; OUTCOME ASSESSMENT; PATHOLOGICAL CRYING; PERTUSSIS; REVIEW; SKIN REDNESS; SWELLING; TETANUS; UNITED STATES; VACCINATION; COMMUNICABLE DISEASES, EMERGING; IMMUNOLOGY; PROCEDURES; WHOOPING COUGH;

COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PERTUSSIS VACCINE; UNITED STATES; VACCINATION; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84920178663     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29576     Document Type: Review

References (73)

1. Notes from the Field. Pertussis - California, January-June 2010. MMWR Morb Mortal Wkly Rep 2010;59:817.
2. Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, Hogg G, Lan R. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis 2012; 205:1220-4; PMID:22416243; http://dx.doi.org/10.1093/infdis/jis178
3. Greenberg DP, Doemland M, Bettinger JA, Scheifele DW, Halperin SA, Waters V, Kandola K; IMPACT Investigators. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussisinactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr Infect Dis J 2009; 28:521-8; PMID:19436236; http://dx.doi.org/10.1097/INF.0b013e318199d2fc
4. Amirthalingam G. Strategies to control pertussis in infants. Arch Dis Child 2013; 98:552-5; PMID:23698594; http://dx.doi.org/10.1136/archdischild-2012-302968
5. Barret AS, Ryan A, Breslin A, Cullen L, Murray A, Grogan J, Bourke S, Cotter S. Pertussis outbreak in northwest Ireland, January - June 2010. Euro Surveill 2010; 15:15; PMID:20822735
6. Lavine JS, Bjornstad ON, de Blasio BF, Storsaeter J. Shortlived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine 2012; 30:544-51; PMID:22119924; http://dx.doi.org/10.1016/j.vaccine.2011.11.065
7. Cherry JD, Brunnel P, Golden G. Report of the Task Force on Pertussis and Pertussis Immunization. Pediatrics 1988; 81(suppl):933-84.
8. Onorato IM,Wassilak SG,Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 1992; 267:2745-9; PMID:1578592; http://dx.doi.org/10.1001/jama.1992.03480200053023
9. Centers for Disease Control and Prevention (CDC). January 1992-June 1995. MMWR Morb Mortal Wkly Rep 1995; 44:525-9; PMID:7603428
10. Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Rauh W, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41; PMID:8531284; http://dx.doi.org/10.1001/jama.1996.03530250041024
11. Liese JG, Meschievitz CK, Harzer E, Froeschle J, Hosbach P, Hoppe JE, Porter F, Stojanov S, Niinivaara K, Walker AM, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997; 16:1038-44; PMID:9384336; http://dx.doi.org/10.1097/00006454-199711000-00007
12. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, Sanden G, Mboup S, Hoffenbach A, Knudsen K, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15:1606-12; PMID:9364690; http://dx.doi.org/10.1016/S0264-410X(97)00100-X
13. Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, uberall M, Laussucq S, Eckhardt T, Meyer M, Engelhardt R, Christenson P. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101:1-11; PMID:9417143; http://dx.doi.org/10.1542/peds.101.1.1
14. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 1989; 115:686-93; PMID:2809899; http://dx.doi.org/10.1016/S0022-3476(89)80643-2
15. De Serres G, Boulianne N, Duval B, Déry P, Rodriguez AM, Massé R, Halperin S. Effectiveness of a whole cell pertussis vaccine in child-care centers and schools. Pediatr Infect Dis J 1996; 15:519-24; PMID:8783349; http://dx.doi.org/10.1097/00006454-199606000-00009
16. Bentsi-Enchill AD, Halperin SA, Scott J, MacIsaac K, Duclos P. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997; 15:301-6; PMID:9139490; http://dx.doi.org/10.1016/S0264-410X(96)00176-4
17. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003; 22:22-7; PMID:12544404; http://dx.doi.org/10.1097/00006454-200301000-00009
18. Christie CD, Marx ML, Marchant CD, Reising SF. The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children. N Engl J Med 1994; 331:16-21; PMID:8202096; http://dx.doi.org/10.1056/NEJM199407073310104
19. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SG. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998; 132:983-8; PMID:9627590; http://dx.doi.org/10.1016/S0022-3476(98)70395-6
20. Trollfors B, Rabo E.Whooping cough in adults. Br Med J (Clin Res Ed) 1981; 283:696-7; PMID:6793129; http://dx.doi.org/10.1136/bmj.283.6293.696
21. Plotkin SA, Orenstein W, Offit PA, eds. Vaccines: Elsevier Saunders, 2013.
22. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68:650-60; PMID:7031583
23. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21:2003-14; PMID:12706690; http://dx.doi.org/10.1016/S0264-410X(02)00770-3
24. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, Chen RT. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351:356-61; PMID:9652634; http://dx.doi.org/10.1016/S0140-6736(97)04334-1
25. Ward KN, Bryant NJ, Andrews NJ, Bowley JS, Ohrling A, Verity CM, Ross EM, Miller E. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics 2007; 120:314-21; PMID:17671057; http://dx.doi.org/10.1542/peds.2006-3743
26. Berkovic SF, Harkin L, McMahon JM, Pelekanos JT, Zuberi SM, Wirrell EC, Gill DS, Iona X, Mulley JC, Scheffer IE. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006; 5:488-92; PMID:16713920; http://dx.doi.org/10.1016/S1474-4422(06)70446-X
27. Reyes IS, Hsieh DT, Laux LC, Wilfong AA. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics 2011; 128:e699-702; PMID:21844054
28. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984; 1:122-6; PMID:6140441; http://dx.doi.org/10.1016/S0140-6736(84)90061-8
29. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6:364-71; PMID:3588110; http://dx.doi.org/10.1097/00006454-198704000-00005
30. Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, Englund JA, Pichichero ME, Deloria MA. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96:548-57; PMID:7659475
31. Noble GR, Bernier RH, Esber EC, Hardegree MC, Hinman AR, KleinD, Saah AJ. Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists. JAMA 1987; 257:1351-6; PMID:3820444; http://dx.doi.org/10.1001/jama.1987.03390100089032
32. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1988; 1:955-60; PMID:2896826
33. Krantz I, Sekura R, Trollfors B, Taranger J, Zackrisson G, Lagergard T, Schneerson R, Robbins J. Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children. J Pediatr 1990; 116:539-43; PMID:2319400; http://dx.doi.org/10.1016/S0022-3476(05)81599-9
34. Isacson J, Trollfors B, Taranger J, MacDowall I, Johansson J, Lagergard T, Robbins JB. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants. Pediatr Infect Dis J 1994; 13:22-7; PMID:8170728; http://dx.doi.org/10.1097/00006454-199401000-00006
35. Trollfors B, Taranger J, Lagergard T, Lind L, Sundh V, Zackrisson G, Lowe CU, Blackwelder W, Robbins JB. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333:1045-50; PMID:7675047; http://dx.doi.org/10.1056/NEJM199510193331604
36. Storsaeter J, Hallander H, Farrington CP, Olin P, Möllby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990; 8:457-61; PMID:2251872; http://dx.doi.org/10.1016/0264-410X(90)90246-I
37. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC, et al.; Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-8; PMID:8538704; http://dx.doi.org/10.1056/NEJM199602083340601
38. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55; PMID:8538705; http://dx.doi.org/10.1056/NEJM199602083340602
39. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334:391-2; PMID:8538712; http://dx.doi.org/10.1056/NEJM1-99602083340609
40. Hallander HO, Gustafsson L. Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience. Expert Rev Vaccines 2009; 8:1303-7; PMID:19803750; http://dx.doi.org/10.1586/erv.09.88
41. Cherry JD. Why do pertussis vaccines fail? Pediatrics 2012; 129:968-70; PMID:22529282; http://dx.doi.org/10.1542/peds.2011-2594
42. Plotkin SA. The pertussis problem. Clin Infect Dis 2014; 58:830-3; PMID:24363332; http://dx.doi.org/10.1093/cid/cit934
43. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-7):1-25; PMID:9091780
44. Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1992; 41(RR-15):1-5; PMID:1406564
45. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, et al.; Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-3):1-34; PMID:16557217
46. Weston WM, Klein NP. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years. Expert Rev Vaccines 2008; 7:1309-20; PMID:18980534; http://dx.doi.org/10.1586/14760584.7.9.1309
47. Centers for Disease Control and Prevention (CDC). FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants. MMWR Morb Mortal Wkly Rep 2003; 52:203-4; PMID:12653460
48. Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR; Pentacel Study Group. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009; 123:301-12; PMID:19117896; http://dx.doi.org/10.1542/peds.2007-3317
49. Yeh SH, Ward JI, Partridge S, Marcy SM, Lee H, Jing J, Curry ES, Howe BJ. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatr Infect Dis J 2001; 20:973-80; PMID:11642632; http://dx.doi.org/10.1097/00006454-200110000-00011
50. Dennehy PH, Bertrand HR, Silas PE, Damaso S, Friedland LR, Abu-Elyazeed R. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008; 122:e1062-6; PMID:18977955; http://dx.doi.org/10.1542/peds.2008-1059
51. DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Package Insert. Sanofi Pasteur, 2002.
52. Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012; 31:64-71; PMID:22094635; http://dx.doi.org/10.1097/INF.0b0-13e31823dce5c
53. Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix TM) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine 2012; 30:668-74; PMID:22064267; http://dx.doi.org/10.1016/j.vaccine.2011.10.065
54. Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, et al. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:383-8; PMID:23104129; http://dx.doi.org/10.1097/INF.0b013e318279e9a9
55. Salmaso S, Mastrantonio P, Wassilak SG, Giuliano M, Anemona A, Giammanco A, Tozzi AE, Ciofi degli Atti ML, Greco D; Stage II Working Group. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine 1998; 16:1270-5; PMID:9682390; http://dx.doi.org/10.1016/S0264-410X(98)00040-1
56. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108:E81; PMID:11694665; http://dx.doi.org/10.1542/peds.108.5.e81
57. Quinn HE, Snelling TL, Macartney KK, McIntyre PB. Duration of protection after first dose of acellular pertussis vaccine in infants. Pediatrics 2014; 133:e513-9; PMID:24515514; http://dx.doi.org/10.1542/peds.2013-3181
58. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, Bogaerts H, Storsaeter J. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003; 21:2015-21; PMID:12706691; http://dx.doi.org/10.1016/S0264-410X(02)00777-6
59. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006; 118:978-84; PMID:16950988; http://dx.doi.org/10.1542/peds.2005-2746
60. Vickers D, Ross AG, Mainar-Jaime RC, Neudorf C, Shah S. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. CMAJ 2006; 175:1213-7; PMID:17098950; http://dx.doi.org/10.1503/cmaj.051637
61. Bettinger JA, Halperin SA, De Serres G, Scheifele DW, Tam T. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J 2007; 26:31-5; PMID:17195702; http://dx.doi.org/10.1097/01.inf.0000247055.81541.04
62. Lavine J, Broutin H, Harvill ET, Bjornstad ON. Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine 2010; 29:11-6; PMID:21034823; http://dx.doi.org/10.1016/j.vaccine.2010.10.029
63. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24 (Suppl):S58-61; PMID:15876927; http://dx.doi.org/10.1097/01.inf.0000160914.59160.41
64. Khan FN, Lin M, Hinkle CJ, Franklin P, Luther R, Woodruff F, Henson K, Lukenbill M, Gutierrez M, Zhu BP. Case-control study of vaccination history in relation to pertussis risk during an outbreak among school students. Pediatr Infect Dis J 2006; 25:1132-6; PMID:17133158; http://dx.doi.org/10.1097/01.inf.0000245099.01427.93
65. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012-9; PMID:22970945; http://dx.doi.org/10.1056/NEJMoa1200850
66. Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126-32; PMID:23188029; http://dx.doi.org/10.1001/jama.2012.14939
67. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730-5; PMID:22423127; http://dx.doi.org/10.1093/cid/cis287
68. Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52; PMID:23478868; http://dx.doi.org/10.1542/peds.2012-1928
69. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131:e1716-22.
70. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454-6; PMID:22851107; http://dx.doi.org/10.1001/jama.2012.6364
71. Liko J, Robison SG, Cieslak PR. Priming with wholecell versus acellular pertussis vaccine. N Engl J Med 2013; 368:581-2; PMID:23388023; http://dx.doi.org/10.1056/NEJMc1212006
72. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131-5; PMID:23425962
73. Baxter R, Bartlett J, Rowhani-Rahbar A, Fireman B, Klein NP. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ 2013; 347: f4249; PMID:23873919; http://dx.doi.org/10.1136/bmj.f4249